



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><br><b>A61K 31/135</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/56739</b><br><br><b>(43) International Publication Date:</b> 11 November 1999 (11.11.99)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>(21) International Application Number:</b> PCT/US99/10146<br><br><b>(22) International Filing Date:</b> 7 May 1999 (07.05.99)<br><br><b>(30) Priority Data:</b><br>60/084,602                      7 May 1998 (07.05.98)                      US<br><br><b>(71) Applicant (for all designated States except US):</b> THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION<br>[US/US]; Suite 403, 1534 White Avenue, Knoxville, TN 37996-1527 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> STEINER, Mitchell, S.<br>[US/US]; 8894 Silverbark Drive, Germantown, TN 38138 (US). RAGHOW, Sharon [US/US]; 1535 Brookline Cove, Germantown, TN 38138 (US).<br><br><b>(74) Agent:</b> COHEN, Mark; The Law Firm of Mark Cohen, 276 Warwick Avenue, Teaneck, NJ 07666 (US). |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> A METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>(57) Abstract</b><br><br><p>This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.</p>                   |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                          |    |                                              |    |                          |
|----|--------------------------|----|------------------------------------------|----|----------------------------------------------|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |                                              | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali                                         | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger                                        | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    | Republic of Korea                        | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakistan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan                                        |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## **A METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER**

5

### **FIELD OF INVENTION**

This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of an agent to prevent the recurrence of, suppression or inhibition of prostate carcinogenesis.

10

### **BACKGROUND OF THE INVENTION**

Prostate cancer is one of the most frequently occurring cancers among men in the United States, with hundreds of thousands of new cases diagnosed each year. Unfortunately, over sixty percent of newly diagnosed cases of prostate cancer are found to be pathologically advanced, with no cure and a dismal prognosis. One approach to this problem is to find prostate cancer earlier through screening programs and thereby reduce the number of advanced prostate cancer patients. Another strategy, however, is to develop drugs to prevent prostate cancer. One third of all men over 50 years of age have a latent form of prostate cancer that may be activated into the life-threatening clinical prostate cancer form. The frequency of latent prostatic tumors has been shown to increase substantially with each decade of life from the 50s (5.3-14%) to the 90s (40-80%). The number of people with latent prostate cancer is the same across all cultures, ethnic groups, and races, yet the frequency of clinically aggressive cancer is markedly different. This suggests that environmental factors may play a role in activating latent prostate cancer. Thus, the development of chemoprevention strategies against prostate cancer may have the greatest overall impact both medically and economically against prostate cancer.

30

Because of the high incidence and mortality of prostate cancer, it is imperative to develop chemoprevention strategies against this devastating disease.

Understanding those factors that contribute to prostate carcinogenesis including the initiation, promotion, and progression of prostate cancer will provide molecular mechanistic clues as to appropriate points of intervention to prevent or halt the carcinogenic process. New innovative approaches are urgently  
5 needed at both the basic science and clinical levels to decrease the incidence of prostate cancer as well as to halt or cause the regression of latent prostate cancer. As the frequency of prostate cancer escalates dramatically at the same ages when men are confronted by other competing causes of mortality, simply slowing the progression of prostate adenocarcinoma may be both a more  
10 suitable and cost effective health strategy.

Various approaches have been taken to the chemoprevention of prostate cancer. Greenwald, "Expanding Horizons in Breast and Prostate Cancer Prevention and Early Detection" in J. Cancer Education, 1993, Vol. 8, No. 2,  
15 pages 91-107, discusses the testing of 5 $\alpha$ -reductase inhibitors such as finasteride for the prevention of prostate cancer. Brawley et al., "Chemoprevention of Prostate Cancer" in Urology, 1994, Vol. 43, No. 5, also mentions 5 $\alpha$ -reductase inhibitors as well as difluoromethylornithine and retinoids as potential chemopreventive agents.

20 Kelloff et al., "Introductory Remarks: Development of Chemopreventive Agents for Prostate Cancer" in Journal of Cellular Biochemistry, 1992, Supplement 16H: 1-8, describes National Cancer Institute preclinical studies of seven agents: all-trans-N-(4-hydroxyphenyl)retinamide, difluoromethylornithine,  
25 dehydroepiandrosterone, liarozole, lovastatin, oltipraz, and finasteride.

Lucia et al., "Chemopreventive Activity of Tamoxifen, N-(4-Hydroxyphenyl)retinamide, and the Vitamin D Analogue Ro24-5531 for Androgen-promoted Carcinomas of the Rat Seminal Vesicle and Prostate" in  
30 Cancer Research, 1995, Vol. 55, pages 5621-5627, reports chemoprevention of prostate carcinomas in Lobund-Wistar rats by tamoxifen, an estrogen response modifier.

As discussed in Potter et al., "A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism" in Carcinogenesis, 1994, Vol. 15, No. 3, pages 439-442, tamoxifen causes liver carcinogenicity in rats, which is attributed to the formation of covalent DNA adducts. This reference also reports that the tamoxifen analogue toremifene, which showed a much lower level of hepatic DNA adduct formation than tamoxifen, is non-carcinogenic.

Toremifene is an example of a triphenylalkene compound described in U.S. Patent Nos. 4,696,949 and 5,491,173 to Toivola et al., the disclosures of which are incorporated herein by reference. The parenteral and topical administration to mammalian subjects of formulations containing toremifene are described in U.S. Patent No. 5,571,534 to Jalonon et al. and in U.S. Patent No. 5,605,700 to DeGregorio et al., the disclosures of which are incorporated herein by reference.

Toremifene-containing formulations for reversing the multidrug resistance to cancer cells to a cytotoxic drug are described in U.S. Patent No. 4,990,538 to Harris et al., the disclosure of which is incorporated herein by reference. U.S. Patent Nos. 5,595,722 and 5,599,844 to Grainger et al., the disclosures of which are incorporated herein by reference, describe methods for identifying agents that increase TGFP levels and for orally administering formulations containing TGFP activators and TGFP production stimulators to prevent or treat conditions characterized by abnormal proliferation of smooth muscle cells, for example, vascular trauma. Disclosed agents for increasing TGFP levels include tamoxifen and its analogue toremifene.

U.S. Patent Nos. 5,629,007 and 5,635,197 to Audia et al., the disclosures of which are incorporated herein by reference, describe a method of preventing the development of prostatic cancer at risk of developing such cancer, for example, a patient having benign prostatic hyperplasia, by administering to the patient an octahydrobenzo[f]quinolin-3-one compound.

U.S. Patent No. 5,595,985 to Labrie, the disclosure of which is incorporated herein by reference, also describe a method for treating benign prostatic hyperplasia using a combination of a 5 $\alpha$ -reductase inhibitor and a compound that binds and blocks access to androgen receptors. One example of a compound that blocks androgen receptors is flutamide.

U.S. Patent Nos. 4,329,364 and 4,474,813 to Neri et al., the disclosures of which are incorporated herein by reference, describe pharmaceutical preparations comprising flutamide for delaying and/or preventing the onset of prostate carcinoma. The preparation can be in the form of a capsule, tablet, suppository, or elixir. Despite these developments, there is a continuing need for agents and methods effective for preventing prostate cancer. The present invention is directed to satisfying this need.


15

### SUMMARY OF THE INVENTION

This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent, toremifene and analogs or metabolites thereof, to prevent recurrence of, treatment, suppression or inhibition of prostate carcinogenesis.

The present invention is directed to a method for preventing prostate carcinogenesis. This invention involves administering to a mammalian subject a pharmaceutical preparation of a chemopreventive agent having the formula:

25



30

wherein  $R_1$  and  $R_2$ , which can be the same or different, are H or OH,  $R_3$  is  $OCH_2CH_2NR_4R_5$ , wherein  $R_4$  and  $R_5$ , which can be the same or different, are H or an alkyl group of 1 to about 4 carbon atoms;

- 5 and their pharmaceutically acceptable carrier, diluents, salts, esters, or N-oxides, and mixtures thereof.

The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects  
10 having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

15

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1:** A graph illustrating the chemopreventive effects of toremifene in the TRAMP model.

- 20 **Figures 2A-2C:** H&E sections illustrating ventral prostate cells in normal mice and prostate carcinoma in TRAMP mice included in the study.

**Figure 3:** Effect of Toremifene on ventral prostate development in the TRAMP mouse.

25

**Figure 4:** Effect of Toremifene on tumor occurrence in the TRAMP mice.

**Figure 5:** Effect of Toremifene on tumor development in the TRAMP model.


- 30 **Figures 6A-6B:** Comparison of placebo vs. Toremifene effects on tumor growth.

### DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method for preventing prostate carcinogenesis; 2) methods for suppressing or inhibiting prostate cancer; 3) methods for reducing the risk of developing prostate cancer; and 4) methods for increasing the survival rate of a subject using the prostate chemopreventive agent, toremifene, analogs and metabolites thereof.

As demonstrated herein, Toremifene is a prostate chemopreventive agent. In the experiments conducted herein, the prostates were actually dissected and evaluated both histologically and by wholemount analysis. Also, Toremifene was tested for the treatment of prostate cancer by treating LNCaP xenografts in nude mice. As is shown, the data is quite dramatic, not only has Toremifene inhibited growth, but actually Toremifene was able to produce regression of the tumors.

The present invention is directed to a method for preventing prostate carcinogenesis. This invention involves administering to a mammalian subject a pharmaceutical preparation of a chemopreventive agent having the formula:




wherein R<sub>1</sub> and R<sub>2</sub>, which can be the same or different, are H or OH, R<sub>3</sub> is OCH<sub>2</sub>CH<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, wherein R<sub>4</sub> and R<sub>5</sub>, which can be the same or different, are H or an alkyl group of 1 to about 4 carbon atoms; and their pharmaceutically acceptable carrier, diluents, salts, esters, or N-oxides, and mixtures thereof.

This invention provides for the use of a pharmaceutical composition for preventing the recurrence of, suppressing or inhibiting prostate carcinogenesis, or increasing the survival rate of a subject having prostate cancer, comprising a chemopreventive agent having the formula:

5

10



15

wherein  $R_1$  and  $R_2$ , which can be the same or different, are H or OH,  $R_3$  is  $OCH_2CH_2NR_4R_5$ , wherein  $R_4$  and  $R_5$ , which can be the same or different, are H or an alkyl group of 1 to about 4 carbon atoms; and their pharmaceutically acceptable carrier, diluents, salts, esters, or N-oxides, and mixtures thereof.

The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

The compound 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene of formula (I), where  $R_1$  and  $R_2$  are each H and  $R_4$  and  $R_5$  are each methyl, is named toremifene. Toremifene has been shown safe and

effective as an anti-tumor compound and exhibits hormonal effects as an estrogenic or as an anti-estrogenic agent, depending on the dosage used. On administration, toremifene has several metabolites that are also biologically active.

5

This invention also provides for use of toremifene analogs or metabolites thereof, which are well known to those skilled in the art. Other examples of chemopreventive agents of formula (I) are the following: 4-chloro-1,2-diphenyl-1-[4-[2-(N-methylamino)ethoxy]phenyl]-1-butene; 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-diethylamino)ethoxy]phenyl]-1-butene; 4-chloro-1,2-diphenyl-1-[4-(aminoethoxy)phenyl]-1-butene; 4-chloro-1-(4-hydroxyphenyl)-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-2-phenyl-1-butene; 4-chloro-1-(4-hydroxyphenyl)-1-[4-[2-(N-methylamino)ethoxy]phenyl]-2-phenyl-1-butene; and 4-chloro-1,2-bis(4-hydroxyphenyl)-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene.

10  
15

The invention encompasses pure (Z)- and (E)- isomers of the compounds and mixtures thereof as well as pure (RR,SS)- and (RS,SR)-enantiomer couples and mixtures thereof.

20

The agent compounds of formula (I) can be prepared according to procedures described in the previously cited U.S. Patent Nos. 4,696,949 and 5,491,173 to Toivola et al.

25 The invention includes pharmaceutically acceptable salts of amino-substituted compounds with organic and inorganic acids, for example, citric acid and hydrochloric acid. The invention also includes N-oxides of the amino substituents of the compounds of formula (I). Pharmaceutically acceptable salts can also be prepared from the phenolic compounds by treatment with inorganic bases, for example, sodium hydroxide. Also, esters of the phenolic compounds can be made with aliphatic and aromatic carboxylic acids, for example, acetic acid and benzoic acid esters.

30

As used herein, "pharmaceutical composition" means therapeutically effective amounts of the agent together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers. A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance. Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines). Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral. In one embodiment the pharmaceutical composition is administered parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially and intratumorally.

30

Further, as used herein "pharmaceutically acceptable carrier" are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and

preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.

The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., *Immunology, Second Ed.*, 1984, Benjamin/Cummings: Menlo Park, California, p. 384). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvant include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvant such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the adjuvant is pharmaceutically acceptable.

Controlled or sustained release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors.

Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral. Compounds modified by the covalent attachment of water-soluble polymers  
5 such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and  
10 Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound adducts less  
15 frequently or in lower doses than with the unmodified compound.

In yet another embodiment, the pharmaceutical composition can be delivered in a controlled release system. For example, the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch,  
20 liposomes, or other modes of administration. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989). In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity of  
25 the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984). Preferably, a controlled release device is introduced into a subject in proximity of the site of inappropriate immune activation or a tumor. Other controlled release systems are discussed  
30 in the review by Langer (Science 249:1527-1533 (1990).

The method of the present invention for preventing prostate carcinogenesis involves administering to a mammalian subject a pharmaceutical preparation comprising chemopreventive agent or a metabolite or salt thereof. The pharmaceutical preparation can comprise the chemopreventive agent alone, or  
5 can further include a pharmaceutically acceptable carrier, and can be in solid or liquid form such as tablets, powders, capsules, pellets, solutions, suspensions, elixirs, emulsions, gels, creams, or suppositories, including rectal and urethral suppositories. Pharmaceutically acceptable carriers include gums, starches, sugars, cellulosic materials, and mixtures thereof. The pharmaceutical  
10 preparation containing the chemopreventive agent can be administered to a subject by, for example, subcutaneous implantation of a pellet; in a further embodiment, the pellet provides for controlled release of chemopreventive agent over a period of time. The preparation can also be administered by intravenous, intraarterial, or intramuscular injection of a liquid preparation, oral administration  
15 of a liquid or solid preparation, or by topical application. Administration can also be accomplished by use of a rectal suppository or a urethral suppository. The pharmaceutical preparation can also be a parenteral formulation; in one embodiment, the formulation comprises a liposome that includes a complex of a chemopreventive agent such as, for example, toremifene and a cyclodextrin  
20 compound, as described in the previously cited U.S. Patent No. 5,571,534 to Jalonon et al.

The pharmaceutical preparations of the invention can be prepared by known dissolving, mixing, granulating, or tablet-forming processes. For oral  
25 administration, the chemopreventive agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into a suitable form for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily  
30 solutions. Examples of suitable inert vehicles are conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders like acacia, cornstarch, gelatin, or with disintegrating agents such as cornstarch, potato

starch, alginic acid, or with a lubricant like stearic acid or magnesium stearate. Examples of suitable oily vehicles or solvents are vegetable or animal oils such as sunflower oil or fish-liver oil. Preparations can be effected both as dry and as wet granules. For parenteral administration (subcutaneous, intravenous, 5 intraarterial, or intramuscular injection), the chemopreventive agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are converted into a solution, suspension, or emulsion, if desired with the substances customary and suitable for this purpose, for example, solubilizers or other auxiliaries. Examples are: sterile liquids such as water and oils, with or 10 without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly 15 for injectable solutions.

The preparation of pharmaceutical compositions which contain an active component is well understood in the art. Typically, such compositions are prepared as an aerosol of the polypeptide delivered to the nasopharynx or as 20 injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, 25 water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.

30 An active component can be formulated into the composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the

polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example,  
5 sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

For topical administration to body surfaces using, for example, creams, gels,  
10 drops, and the like, the chemopreventive agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.

15 In another embodiment, the active compound can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

20

The pharmaceutical compositions of the present invention are particularly useful for treating a subject having an elevated risk of developing prostate cancer. High-risk subjects include, for example, those having benign prostatic hyperplasia, prostatic intraepithelial neoplasia (PIN), or an abnormally high level  
25 of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.

Further, the prostate chemopreventive agent may be administered in combination with other cytokines or growth factors include but are not limited to:  
30 IFN  $\gamma$  or  $\alpha$ , IFN- $\beta$ ; interleukin (IL) 1, IL-2, IL-4, IL-6, IL-7, IL-12, tumor necrosis factor (TNF)  $\alpha$ , TNF- $\beta$ , granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage CSF (GM-CSF); accessory molecules, including

members of the integrin superfamily and members of the Ig superfamily such as, but not limited to, LFA-1, LFA-3, CD22, and B7-1, B7-2, and ICAM-1 T cell costimulatory molecules.

- 5 The chemopreventive agent may precede or follow a DNA damaging agent treatment by intervals ranging from minutes to weeks. Protocols and methods are known to those skilled in the art. DNA damaging agents or factors are known to those skilled in the art and means any chemical compound or treatment method that induces DNA damage when applied to a cell. Such agents and
- 10 factors include radiation and waves that induce DNA damage such as, gamma-irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, and the like. A variety of chemical compounds, also described as "chemotherapeutic agents", function to induce DNA damage, all of which are intended to be of use in the combined treatment methods disclosed herein. Chemotherapeutic agents
- 15 contemplated to be of use, include, e.g., adriamycin, 5-fluorouracil (5FU), etoposide (VP-16), camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP) and even hydrogen peroxide. The invention also encompasses the use of a combination of one or more DNA damaging agents, whether radiation-based or actual compounds, such as the use of X-rays with cisplatin or the use of cisplatin
- 20 with etoposide.

In another embodiment one may irradiate the localized tumor site with DNA damaging radiation such as X-rays, UV-light, gamma-rays or even microwaves. Alternatively, the tumor cells may be contacted with the DNA damaging agent

25 by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a DNA damaging compound such as, adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, or more preferably, cisplatin. Agents that damage DNA also include compounds that interfere with DNA replication, mitosis and chromosomal

30 segregation. Such chemotherapeutic compounds include adriamycin, also known as doxorubicin, etoposide, verapamil, podophyllotoxin, and the like.

Other factors that cause DNA damage and have been used extensively include what are commonly known as gamma -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage DNA, on the precursors of DNA, the replication and repair of DNA, and the assembly and maintenance of chromosomes.

As can be readily appreciated by one of ordinary skill in the art, the methods and pharmaceutical compositions of the present invention are particularly suited to administration to a mammal, preferable a human subject.

Intermediate endpoint biomarkers are measurable biologic alterations in tissue that occur between the initiation of and the development of frank neoplasia. It is hypothesized that modulation of one or more intermediate endpoint biomarkers by a chemopreventive agent may reflect true inhibition of carcinogenesis. A biomarker would be validated if the final endpoint, cancer incidence, were also reduced by the putative chemopreventive agent. Intermediate biomarkers in cancer may be classified into the following groups: histologic, proliferation, differentiation and biochemical markers. In any chemoprevention strategy, the availability of histologically recognizable and accepted precancerous lesions constitutes an important starting point. For the prostate, a possible histological marker is prostatic intraepithelial neoplasia (PIN), which is a precancerous precursor of prostatic adenocarcinoma. PIN appears as an abnormal proliferation within the prostatic ducts of premalignant foci of cellular dysplasia and carcinoma in situ without stromal invasion. PIN and histological prostate cancer are morphometrically and phenotypically similar. Thus, the development of high grade PIN may represent an important step in the progression pathway whereby the normal prostate develops PIN, histological prostate cancer, invasive clinical prostate cancer, and metastases.

The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

5

## **EXPERIMENTAL DETAILS SECTION**

### **Example I: Transgenic Adenocarcinoma Mouse Prostate**

The study of prostate cancer chemoprevention has been hindered by the lack  
10 of appropriate animal models. The recent development of the transgenic  
adenocarcinoma mouse prostate (TRAMP) model enables the study of  
chemoprevention. In the TRAMP model, which is described in Greenberg et al.,  
"Prostate cancer in a transgenic mouse," Proc. Natl Acad. Sci. USA, 1995, Vol.  
92, pages 3439-3443, the PB-SV40 large T antigen (PB-Tag) transgene is  
15 expressed specifically in the epithelial cells of the murine prostate. As a result,  
this model has several advantages over currently existing models: 1) mice  
develop progressive forms of prostatic epithelial hyperplasia as early as 10  
weeks and invasive adenocarcinoma around 18 weeks of age; 2) the metastatic  
spread of prostate cancer pattern mimics human prostate cancer with the  
20 common sites of metastases being lymph node, lung, kidney, adrenal gland, and  
bone; 3) the development as well as the progression of prostate cancer can be  
followed within a relatively short period of 10-30 weeks; 4) the tumors arise with  
100% frequency; and 5) the animals may be screened for the presence of the  
prostate cancer transgene prior to the onset of clinical prostate cancer to directly  
25 test treatment with chemopreventive agents that may alter prostate  
carcinogenesis.

The TRAMP transgenic mouse model is an excellent *in vivo* model to determine  
the mechanisms of initiation and promotion of prostate *cancer* and to test the  
30 effectiveness of potential chemopreventive agents. These mice progressively  
develop prostatic epithelial hyperplasia, PIN, and then prostate cancer within a  
short period (<17 weeks).

Chemopreventive treatment of hybrid TRAMP mice is initiated 30 days postnatally, using chemopreventive agents at a level of about 0.5-50 mg/kg of subject weight/day, preferably about 6-30 mg/kg of subject weight/day. The chemopreventive agents are conveniently processed into 21-day and 90-day pellets (prepared by Innovative Research of America, Sarasota, FL) and delivered as subcutaneous implants. Control animals receive placebo implants. In each drug treatment group, animals are sacrificed at 5,7, 10, 15,20,25,30,40, and 50 weeks of age until the development of a palpable tumor. Blood is collected and pooled per treatment time point to evaluate changes in serum testosterone and estradiol. Prostatic tissues are harvested for morphometric, histologic, and molecular studies.

The following test procedures are employed:

1) Prostate wholemount analysis is serially performed to detect changes in prostate ductal morphology over time with and without treatment; examples are shown in Fig. 2. Tissue sections are evaluated histologically by H&E and Masson-trichrome standard staining. The emergence of PIN is assessed and graded (I-mild to III-severe).

2) Serum estradiol and total testosterone levels are measured (RIA) for each age interval to assess any changes in these hormones as a result of chemopreventive agents.

#### **Example 2: Immunohistochemistry Data Analysis**

Microscopy images of each tissue section are evaluated by using computer-assisted (Mac 9500-I 32 computer and monitor) image quantitation (NIH-Image 1.6 PPC) using Kodak DCS 460 camera on Nikon Microphot-FX microscope and quantitated by using a color-assisted quantitative system image analysis (IPLab Spectrum 3.1, Scanalytics, Inc., VA) that discriminates color differences of stained tissue sections. Thresholds are set to identify various tissue components of the prostate. The area pixel densities corresponding to each of these tissue components are calculated for each full screen of the color monitor. A total of 5

screens per prostate section are averaged. Immunohistochemical images can be digitalized and quantitated to enable statistical evaluation by determination of sample correlation coefficients and probability (2-tailed).

### 5    **Example 3:                    Study of Chemopreventive Activity**

A study was undertaken to test the efficacy of chemopreventive agents in TRAMP transgenic animals (PBT ag X FVBwt)(provided by Dr. Norman Greenberg, Baylor College of Medicine, TX). These mice showed preliminary  
10    signs of cancer as early as 10 weeks. The TRAMP transgenic male litters were screened for the Large T ag transgene, and the positive males were used in the study. The antiestrogen toremifene, which was to be tested for its possible chemopreventive effects, was incorporated in customized pellets (Innovative Research of America, Sarasota, FL), and chemopreventive treatment of mice  
15    was initiated postnatally at 30 days (average mouse weight 14g). Four groups of 10-12 animals each received subcutaneous implantations of 90 day-release toremifene-containing pellets. The diffusible drug dosage, adjusted for growth related changes in weight, was designed to deliver either a low dose (6mg/kg) or a high dose (30mg/kg) of toremifene. Control animals (n=10) received placebo  
20    implants. The efficacy of the treatment was measured by the absence of palpable tumor formation. The murine prostate tumors were harvested and evaluated by molecular and histological techniques.

Using the TRAMP transgenic model of prostate cancer, in which every animal  
25    that inherits the prostate cancer gene develops prostate cancer, it was demonstrated that toremifene both increases the latency and decreases the incidence of prostate cancer.

As shown in Figure 1 the effects of low and high dose toremifene were both  
30    effective. Tumor formation in the TRAMP mouse ventral prostate was noted at week 17 for the placebo group (n=10), at week 19 for the high dose toremifene-treated group(n=12), and at week 28 for the low dose toremifene-treated group

(n=12). Thus, 5 treatment by toremifene substantially increased the latency period by up to 11 weeks for the development of cancer in the ventral prostate of TRAMP mice.

- 5 Since the toremifene-treated animals did not reach the 50% tumor development point during the period of the study, the time in which 25% of the animals had tumors was compared among groups. Tumors were palpable in 25% of 10 the animals by week 23 in the placebo group and by 30-31 weeks in the high and low toremifene groups, a delay of 7-8 weeks. Both low toremifene and high  
10 toremifene vs placebo were significant by log rank and Wilcoxon statistical analysis, as shown in Table 1 below.

Table 1 - Statistical Analysis

|    |                                    |          |
|----|------------------------------------|----------|
| 15 | Log-Rank                           | Wilcoxon |
|    | P                                  | p        |
|    | Low toremifene vs placebo 0.0003 * | 0.0004*  |
|    | High toremifene vs placebo 0.0017* | 0.0071*  |

\*significance  $P < 0.05$

20

At week 33, a point when all of the control animals had developed tumors, 72% of the low dose and 60% of the high dose toremifene-treated animals were still tumor-free. Thus, toremifene treatment at both low and high dosages resulted in a greatly decreased incidence of tumors in the ventral prostate of TRAMP  
25 mice.

These results, obtained in accordance with the present invention, would not have been predicted from those reported in the aforementioned paper of Lucia et al., which describes the administering at two dosage levels of tamoxifen, a close  
30 structural analog of toremifene, to Lobund-Wistar rats having prostate carcinomas induced by treatment with a combination of an initiator and a promoter. In the Lucia et al. reference, it is reported that only 22-26% of the

animals receiving the lower dose and only 32-50% of those receiving the higher dose of tamoxifen remained free of tumors in the anterior prostate. It should be noted that the anterior prostate of a rodent, unlike its ventral prostate, has no corresponding segment in the prostate of a human subject.

5

In Lucia et al., it is further stated that the initiator-promoter combination employed in the described procedures, although effective in inducing cancer in the anterior prostate of the test animals, failed to induce carcinomas in the ventral prostate. Therefore there is no basis to expect a chemopreventive effect  
10 on tumors in the ventral prostate by administering tamoxifen to Lobund-Wistar rats or to humans.

As already discussed, administering toremifene produces a substantial chemopreventive effect against tumors in the ventral prostate of TRAMP mice.  
15 This result is encouraging for a similar beneficial effect on human subjects, whose prostate does include a segment corresponding to the ventral prostate of rodents.

#### **Example 4: Histological Examination of Prostate Tissue**

20

Tumors from the placebo and high toremifene- treated groups taken at the time of palpation were evaluated histologically. Figure 2A is an H&E section of the ventral prostate of a 17-week-old normal adult mouse. Figure 2B, a section of the ventral prostate of a placebo-treated 16-week-old TRAMP mouse, shows  
25 that, unlike the normal prostate structure depicted in Figure 2A, the TRAMP mouse ventral prostate is characterized by sheets of undifferentiated, anaplastic cells with a high mitotic index. In contrast, as shown in Figure 2C, the prostate of a toremifene-treated 30-week-old TRAMP mouse retains much of the normal glandular architecture and has tumors with a more differentiated structure, the  
30 mitotic index being much lower than that for the placebo-treated animal. These results indicate that toremifene, even at low dosage, is able to suppress prostate carcinogenesis in the TRAMP model.

**EXAMPLE 5 :      Use of Chemopreventive Efficacy of Toremifene  
Against Prostate Cancer in the TRAMP Mouse Model**

5    This experiment confirms and demonstrates the chemopreventive efficacy of  
toremifene. This present study focuses on the histological and molecular  
changes associated with development of prostate tumor in control animals and  
the mechanism of toremifene chemopreventive action with TRAMP animals  
which are bred, screened and treated with sustained-release drug pellets. At  
10    predetermined times, groups of 5 animals were sacrificed and their prostates  
were removed for analysis. The prostate glands were evaluated for the presence  
of tumor by histology, wholemount dissections, and large T antigen  
immunohistochemistry. To date, the Placebo and the Toremifene treatments  
have been completed for the 7, 10, 15 and 20 week time-points and the results  
15    are described below.

*Results:* Prostatic wholemounts for 7, 10, 15, and 20 weeks for the various groups  
have been completed. Wholemount analysis revealed that placebo treated mice  
developed prostate tumors by 15-20 weeks of age similar to the previous pilot  
20    study. Moreover, the Toremifene treated animals had a delay in the occurrence  
of prostate cancer up to 20 weeks (Figure 3). By 20 weeks, there is a striking  
delay in tumor occurrence in the Toremifene treated group up to 35 weeks  
(Figure 4). These data confirm that even with a more sensitive assessment of  
tumorigenicity, Toremifene exhibited chemopreventive activity. For histological  
25    evaluation, tissue samples were fixed, processed and paraffin embedded.  
Sections (5µm thick) were cut and stained by routine H&E method. Toremifene  
inhibited the ductal development and tissue differentiation (compare the 17  
weeks TRAMP mouse prostate tumor vs. wildtype (Figure 4) ; b) Toremifene  
treated prostate histology vs. Placebo at 15 weeks (Figure 5) Qualitatively,  
30    immunohistochemistry of Placebo and Toremifene treated tissues showed  
presence of T-antigen in the ventral prostate. Thus, the chemopreventive activity  
seen by

Toremifene does not appear to be by suppression of the probasin promoter in the TRAMP model.

5 *Conclusions:* The ability of Toremifene to prevent the occurrence of prostate cancer in the TRAMP model has been confirmed utilizing more sensitive techniques to assess tumor formation. The mechanism of Toremifene's chemopreventive effects does not appear to be through loss of the transgene for the Large T- antigen protein.

10 **EXAMPLE 6 : Toremifene Induces Regression of Established Human Prostate Cancer Tumors in the Nude Mouse Model**

Prostate cancer currently remains the most commonly diagnosed cancer in American males. However, questions remain about the etiology and treatment  
15 of this disease especially in advanced forms. Hormone therapy remains the standard method of treatment for recurrent and advanced prostate cancer despite the common development of hormone refractory disease. Therefore, new approaches for the prevention and treatment of prostate cancer are needed to accommodate the increasing number of men diagnosed with this disease.  
20 The experiments and results below demonstrate that toremifene suppresses hormone sensitive LNCaP tumor growth in athymic nude mice.

*Materials and Methods:* One million LNCaP cells in Matrigel were subcutaneously injected into each flank of athymic nude mice. A total 40 mice  
25 were injected. After approximately 3-4 weeks, visible tumors developed. After recording the tumor size in two dimensions, the mice were divided into placebo and treatment groups based on equivalent tumor burden. A single pellet (placebo versus toremifene 35 mg) was subcutaneously implanted between the scapulae of each mouse. Weekly measurements of the tumor size were  
30 recorded. Tumor volume was calculated (tumor volume =  $0.5 (L + W) \times L \times W \times 0.5236$ , where L = tumor length and W = width). The tumor volume at the time of pellet implantation served as the point of reference for future comparison of

that tumor's size variation. The weekly variations of each tumor volume were recorded as percent differentiation from the original measurement at pellet implantation.

- 5 *Results:* Two mice died soon after pellet implantation due to mortal wounds from other mice. One mouse treated with toremifene was excluded from the study due to excessive tumor hemorrhage and hematoma development. All mice developed visible tumors unilaterally or bilaterally. Each tumor was followed independently for the duration of the study. Twenty-four tumors were treated with
- 10 placebo and 28 tumors were treated with toremifene. The results are shown in Table 2 and Figure 6A and 6B.

Table 2

15

| <u>PLACEBO GROUP</u> |           |                                                          |
|----------------------|-----------|----------------------------------------------------------|
| <u>Week</u>          | <u>N=</u> | <u>% Change in volume relative to day 0 of treatment</u> |
| 3                    | 11        | 9.44                                                     |
| 4                    | 8         | 115.27                                                   |
| 5                    | 8         | 271.71                                                   |
| 20 6                 | 8         | 600.88                                                   |

| <u>TOREMIFENE</u> |           |                                                          |
|-------------------|-----------|----------------------------------------------------------|
| <u>Week</u>       | <u>N=</u> | <u>% Change in volume relative to day 0 of treatment</u> |
| 25 3              | 11        | -34.58                                                   |
| 4                 | 7         | -61.01                                                   |
| 5                 | 7         | -74.51                                                   |
| 6                 | 5         | -61.72                                                   |


- 30 The follow-up interval will be extended on the currently reported population and data on additional animals are presently being collected.

*Conclusion:* Toremifene inhibits and induces regression of established LNCaP tumors. Although the mechanism by which toremifene exerts this effect is unknown, the ability to produce these effects supports the use of Toremifene as a treatment for prostate cancer and to prevent the recurrence of prostate cancer

5 in high risk patients with established prostate cancer micrometastases.

**WHAT IS CLAIMED IS:**

1. A method for preventing prostate carcinogenesis comprising:  
administering to a mammalian subject a pharmaceutical  
preparation comprising a chemopreventive agent having the  
formula:




wherein  $R_1$  and  $R_2$ , which can be the same or different, are H or OH;  $R_3$  is  $OCH_2CH_2NR_4R_5$ , wherein  $R_4$  and  $R_5$ , which can be the same or different, are H or an alkyl group of 1 to about 4 carbon atoms;  
and their pharmaceutically acceptable salts, esters, or N-oxides, and mixtures thereof.

2. The method according to claim 1, wherein said pharmaceutical preparation further comprises a pharmaceutically acceptable carrier.
3. The method according to claim 2, wherein said carrier is selected from the group consisting of a gum, a starch, a sugar, a cellulosic material, and mixtures thereof.

4. The method according to claim 1, wherein said administering comprises: subcutaneously implanting in said subject a pellet containing said pharmaceutical preparation.
5. The method according to claim 4, wherein said pellet provides for controlled release of said pharmaceutical preparation over a period of time.
6. The method according to claim 1, wherein said administering intravenously, intraarterially, or intramuscularly injecting in said subject said pharmaceutical preparation in liquid form.
7. The method according to claim 1, wherein said administering orally administering to said subject a liquid or solid preparation containing said pharmaceutical preparation.
8. The method according to claim 1, wherein said administering topically applying to skin surface of said subject said pharmaceutical preparation.
9. The method according to claim 1, wherein said pharmaceutical preparation is selected from the group consisting of a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, and a suppository.
10. The method according to claim 9, wherein said suppository is a rectal suppository or a urethral suppository.
11. The method according to claim 1, wherein said pharmaceutical preparation is a parenteral formulation.

12. The method according to claim 11, wherein said parenteral formulation comprises a liposome comprising a complex of said chemopreventive agent and a cyclodextrin compound.
13. The method according to claim 1, wherein said chemopreventive agent comprises toremifene, its N-oxide, pharmaceutically acceptable salts, and mixtures thereof.
14. The method according to claim 1, wherein said administering is carried out at a dosage of about 0.5 mg/kg of subject weight/day to about 50 mg/kg of subject weight/day of said chemopreventive agent.
15. The method according to claim 14, wherein said administering is carried out at about 6 mg/kg of subject weight/day to about 30 mg/kg of subject weight/day of said chemopreventive agent.
16. The method according to claim 1, wherein said subject has an elevated risk of prostate cancer.
17. The method according to claim 16, wherein said subject has benign prostatic hyperplasia, prostatic intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA).
18. A method for preventing the recurrence of, suppressing or inhibiting prostate carcinogenesis, or increasing the survival rate of a subject having prostate cancer comprising: administering to a mammalian subject a pharmaceutical preparation comprising a chemopreventive agent having the formula:



wherein  $R_1$  and  $R_2$ , which can be the same or different, are H or OH;  $R_3$  is  $OCH_2CH_2NR_4R_5$ , wherein  $R_4$  and  $R_5$ , which can be the same or different, are H or an alkyl group of 1 to about 4 carbon atoms;

and their pharmaceutically acceptable salts, esters, or N-oxides, and mixtures thereof.




FIGURE 1  
SHEET 1/8

Figure 2



A. Normal adult mouse ventral prostate 17 wk  
(mag 200x)



B. Prostate adenocarcinoma in placebo  
treated TRAMP mice 16 wk (mag 200x)



C. Prostate adenocarcinoma in toremifene  
treated TRAMP mice 30 wk (mag 200x)

Figure 3

Effect of Toremifene on Ventral Prostate Development in the TRAMP mouse






FIGURE 4  
SHEET 5/8







Effect of Toremifene on tumor development in the TRAMP model (H&E stain of Prostate tissue)

6/6

Figure 6



| <u>Time after</u><br><u>treatment</u> | <u>% change relative</u><br><u>to day 0</u> |
|---------------------------------------|---------------------------------------------|
| Week 3 (n=11)                         | 9.44                                        |
| Week 4 (n=8)                          | 115.27                                      |
| Week 5 (n=8)                          | 271.71                                      |
| Week 6 (n=8)                          | 600.88                                      |



| <u>Time after</u><br><u>treatment</u> | <u>% change relative</u><br><u>to day 0</u> |
|---------------------------------------|---------------------------------------------|
| Week 3 (n=12)                         | -34.58                                      |
| Week 4 (n=8)                          | -61.01                                      |
| Week 5 (n=8)                          | -74.51                                      |
| Week 6 (n=6)                          | -61.72                                      |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/10146

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                          | Relevant to claim No. |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | WO 94 12162 A (WAERRI ANNI MAIJA ;ALANEN KURKI LEENA MARIA (FI); AUVINEN PETRI OL)<br>9 June 1994 (1994-06-09)<br>abstract<br>page 10, paragraph 2<br>page 11, paragraph 4; claims 1-8; example 4                           | 1-18                  |
| X          | EP 0 095 875 A (FARMOS GROUP LTD)<br>7 December 1983 (1983-12-07)<br>abstract<br>page 3, line 22,23<br>page 28, line 30,31<br>page 31, line 5-11; claims 9,19; example 28; tables 2,3<br>page 35, line 32-35<br>---<br>-/-- | 1-18                  |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 October 1999

Date of mailing of the international search report

20/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 99/10146

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                   | Relevant to claim No. |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| A          | WO 95 26720 A (PHARMOS CORP ;BIEGON ANAT (IL); BREWSTER MARCUS (US))<br>12 October 1995 (1995-10-12)<br>abstract<br>claims 1,31                                                                                                                                      | 1-12,<br>14-18        |
| P,X        | WO 98 58634 A (KURKELA KAUKO ;AF URSIN KAIJA (FI); KANGAS LAURI (FI); KIESVAARA J) 30 December 1998 (1998-12-30)<br>abstract; figure 2<br>page 3, line 30 -page 4, line 3<br>page 5, line 22 -page 6, line 3; table 1<br>page 6, line 28 -page 7, line 2; claims 1,2 | 1-18                  |
| X          | NEVALANINE ET AL.: "Hormone regulation of human prostate in organ culture"<br>CANCER RESS.,<br>vol. 53, no. 21, 1993, pages 519-5207,<br>XP002117653<br>abstract                                                                                                     | 1-18                  |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 10146

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-18  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-18  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10146

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Publication<br>date                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WO 9412162 A                              | 09-06-1994          | AU 687767 B<br>AU 5564994 A<br>CA 2150714 A<br>EP 0671909 A<br>JP 8503848 T<br>US 5726058 A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 05-03-1998<br>22-06-1994<br>09-06-1994<br>20-09-1995<br>30-04-1996<br>10-03-1998                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| EP 0095875 A                              | 07-12-1983          | FI 821879 A<br>GB 2126576 A<br>AT 383344 B<br>AT 192983 A<br>AT 22064 T<br>AU 556608 B<br>AU 1494683 A<br>BG 60760 B<br>CA 1185977 A<br>DD 230864 A<br>DK 236583 A<br>DK 236683 A,B,<br>FI 831584 A,B,<br>HK 8389 A<br>IE 55023 B<br>JP 1739006 C<br>JP 4019973 B<br>JP 58216129 A<br>JP 1867986 C<br>JP 3007239 A<br>JP 5079654 B<br>JP 2105540 C<br>JP 6056724 A<br>JP 7042241 B<br>JP 1959197 C<br>JP 6078257 B<br>JP 6100485 A<br>LT 2243 R<br>LU 88803 A<br>LV 5066 A<br>NZ 204349 A<br>SG 65488 G<br>SU 1508955 A<br>ZA 8303803 A<br>US 5491173 A<br>US 4996225 A<br>US 4696949 A | 28-11-1983<br>28-03-1984<br>25-06-1987<br>15-11-1986<br>15-09-1986<br>13-11-1986<br>19-01-1984<br>29-02-1996<br>23-04-1985<br>11-12-1985<br>28-11-1983<br>28-11-1983<br>28-11-1983<br>03-02-1989<br>25-04-1990<br>26-02-1993<br>31-03-1992<br>15-12-1983<br>26-08-1994<br>14-01-1991<br>04-11-1993<br>06-11-1996<br>01-03-1994<br>10-05-1995<br>10-08-1995<br>05-10-1994<br>12-04-1994<br>15-11-1993<br>05-11-1996<br>10-06-1993<br>20-03-1985<br>16-06-1989<br>15-09-1989<br>29-02-1984<br>13-02-1996<br>26-02-1991<br>29-09-1987 |
| WO 9526720 A                              | 12-10-1995          | US 5650425 A<br>AU 695941 B<br>AU 2201795 A<br>BR 9507281 A<br>CA 2186604 A<br>EP 0754036 A<br>HU 76061 A<br>JP 9511506 T<br>NZ 283648 A                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22-07-1997<br>27-08-1998<br>23-10-1995<br>23-09-1997<br>12-10-1995<br>22-01-1997<br>30-06-1997<br>18-11-1997<br>19-12-1997                                                                                                                                                                                                                                                                                                                                                                                                         |
| WO 9858634 A                              | 30-12-1998          | AU 7920198 A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 04-01-1999                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |